Our qualitative research with patients who have experienced significant weight loss reveals critical gaps in care that represent both challenges and opportunities for healthcare stakeholders.
A growing majority of Americans (74% up from 66% a year ago) see new medications showing potential to treat obesity, according to new data from the Ipsos Consumer Tracker.
Despite media discussions around the drugs, only around a third across 30 countries have heard about the drugs, with a lot of the discourse taking place via social media according to the Ipsos Health Service Report.
GLP-1s are more than just weight loss drugs. They're a chance to rewrite our evolutionary story, to take control of our biology in a way never before possible.
One of this century’s biggest game-changers will likely be a novel drug class that’s showing unprecedented success, or the promise of it, in treating some of the world’s most prevalent conditions.
More than half of Americans would be interested in taking a new 'safe and effective' weight loss treatment, according to new data from the Ipsos Consumer Tracker